Senate leaves FTC provision off finance reform
This article was originally published in The Tan Sheet
Executive Summary
A congressional conference committee will decide whether to include a provision in financial services reform legislation provision that dramatically expands the Federal Trade Commission's rulemaking authority. The Senate passed a version of the Wall Street Reform and Consumer Protection Act, H.R. 4173, without a provision the House included that amends the FTC Act by removing procedural requirements from the commission's rulemaking and enforcement capabilities (1"The Tan Sheet" April 26, 2010). Dietary supplement industry trade groups and other industry organizations lobbied against the provision that would enable FTC to adopt trade regulations using the Administrative Procedure Act rulemaking procedure and no longer require the agency to obtain congressional approval before undertaking formal rulemaking procedures. The House and Senate will appoint conference committee members to negotiate a final bill that resolves differences over the FTC provision and other sections of the extensive legislation
You may also be interested in...
FTC Provision In Finance Reform Bill Could Bite Supplement Firms
Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker